Our findings provide important implications for the treatment of microcystic LM in human and suggest that therapies targeting the key upstream pathway in combination with PI3K pathway inhibition may be relevant for other PIK3CA-driven pathologies. This evidence concerns the gene PIK3CA and lymphangioma.